RCS - OptiBiotix Health - Slimbiome study results

OptiBiotix HealthAnnouncement

15/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230315:nRSO9655Sa&default-theme=true

RNS Number : 9655S  OptiBiotix Health PLC  15 March 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

SlimBiome® human study results

Shows SlimBiome® reduces hunger and food cravings

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that it has completed a third human study on SlimBiome®.

 

The study followed recommended industry guidelines and was designed to
investigate the impact of a single dose of SlimBiome® in the presence of 50g
sugar (12 teaspoons) on 20 healthy volunteers on their glycaemic response,
hunger, and cravings. Blood samples were obtained at 0 (fasting), 15, 30, 45,
60, 75, 90, 120 and 150min post intervention intake.  Feelings of hunger,
fullness, desire to eat, and amount of food desired were assessed at 0, 75 and
150min using the visual analogue scale, a questionnaire used in nutrition
research to assess appetite and food intake.

 

The results showed that when compared to sugar alone, volunteers taking
SlimBiome® experienced significant changes to important appetite and hunger
regulation parameters including:-

 

·    a statistically significant reduction (15.4%) in the insulin response
(p=0.02)

·    statistically significant reduced feelings of hunger compared to
sugar (p=0.038)

·    statistically significant greater feelings of fullness compared to
sugar (p=0.021)

·    trend for lower desire to eat compared to sugar.

 

No safety, compliance, or tolerance issues were reported by volunteers. The
results of this study provide further evidence of the ability of a single dose
of SlimBiome® to moderate the impact of the ingestion of a large amount of
sugar by reducing the insulin response.  A reduced insulin response has been
correlated with increased satiety or fullness.  The results from the visual
analogue questionnaire supported this correlation with volunteers taking
SlimBiome® showing significant reductions in hunger, increased fullness, and
a reduced desire to eat.  The results are consistent with consumer feedback
and customer product reviews who report feeling less hungry leading to reduced
snacking and lower food intake leading to an average weight loss of 1.2kg per
week.

 

These findings show SlimBiome® can have a role as a functional ingredient by
itself as in SlimBiome Medical®, in meal replacements as in GoFigure®, or as
part of a healthy snack in controlling hunger and desire to eat as part of a
calorie controlled diet.

 

 

Stephen O'Hara, CEO of OptiBiotix, commented: "The recent approval of the
injectable drug semaglutide by NICE has generated pharmaceutical and consumer
interest in products which can have an impact on weight management by helping
users reduce hunger and food cravings with sales forecast to reach $3.69bn by
2025(1). This recent study on SlimBiome® is one of three independent human
studies which all show an ability to reduce hunger and food cravings leading
to a reduction in food intake and weight loss. This effect is similar to that
attributed to semaglutide, albeit by a different mechanism, and opens up
opportunities for pharma companies looking to market similar non-invasive OTC
products.

"This new approach to weight loss, given greater prominence by approval of
drugs like semaglutide, suggest that hunger free dieting is now a consumer
choice and that the use of SlimBiome® by itself or its incorporation into
food or snack products can help customers manage weight loss by reducing food
intake without hunger and food cravings."

(1) Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy |
pharmaphorum
(https://pharmaphorum.com/news/novo-nordisk-eyes-obesity-sales-of-3-7bn-in-2025-thanks-to-wegovy/)

 

For further information, please contact:

 

 OptiBiotix Health plc                           www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cenkos Securities plc (Joint Broker)            Tel: 020 7397 8900
 Callum Davidson
 Michael Johnson / Russell Kerr (Sales)

 Peterhouse Capital Limited (Joint Broker)       Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                 Mob: 07876 741 001
 Anna Dunphy

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAJIMFTMTABBFJ